Drugs/Recall·openFDA/drug

Dabur India Limited — Class II: Lucky Super Soft, First Aid Triple Antibiotic Ointment, Bacitracin zinc 400 units, neomyci

MediumPublished Jun 24, 2026· AI-analyzed Jun 30, 2026View original FDA source
AI-generated regulatory interpretation. The four sections below are an analyst-style summary produced by an AI model from the original FDA source. Always verify against the source before any regulatory, clinical, or commercial decision.
What happened

Dabur India Limited has initiated a Class II recall for Lucky Super Soft First Aid Triple Antibiotic Ointment due to CGMP deviations and deficiencies identified during an FDA inspection.

Who it affects

This recall affects Dabur India Limited, Delta Brands Inc., and entities involved in the distribution or retail of Lucky Super Soft Triple Antibiotic Ointment (UPC 8 08829 10372 4).

Why it matters

The classification as a Class II recall indicates that the CGMP deficiencies may lead to temporary or medically reversible adverse health consequences. This enforcement action highlights the FDA's focus on manufacturing standards for OTC topical products produced at international facilities. For regulatory professionals, this demonstrates the risk associated with supply chain oversight and the importance of pre-emptive vendor audits.

Practical takeaway

Quality teams should verify if any current inventory is sourced from this contract manufacturer. Compliance officers should review existing CGMP audit reports for overseas suppliers to ensure site-specific deficiencies regarding topical ointment production are addressed.

FDA source material

Class II. Reason: CGMP Deviations; deficiencies observed during FDA inspection. Product: Lucky Super Soft, First Aid Triple Antibiotic Ointment, Bacitracin zinc 400 units, neomycin sulphate 3.5 mg, polymyxin B sulphate 5000 units, Net Wt. 0.5 oz (14g) tubes, Manufactured for Delta Brands Inc., 580 White Plains Rd., Tarrytown, NY 10591 USA, Made in India, UPC 8 08829 10372 4.. Firm: Dabur India Limited (Dadra And Nagar Haveli India). Status: Ongoing.

Open in openFDA / FDA.gov
AI-generated interpretation. Always verify critical decisions against the original FDA source. Generated with google/gemini-3-flash-preview.